Assessment of the Cow’s Milk-related Symptom Score (CoMiSS) as a diagnostic tool for cow’s milk protein allergy: a prospective, multicentre study in China (MOSAIC study)

Yvan Vandenplas,1 Zheng-Yan Zhao,2 Rajat Mukherjee,3 Christophe Dupont,4 Philippe Eigenmann,5 Mikael Kuitunen,6 Carmen Ribes Koinicxx,7 Hania Szajewska,8 Andrea von Berg,9 Kateřina Bajerová,9 Rosan Meyer,10 Silvia Salvatore,11 Raanan Shamir,12 Anette Järvi,13 Ralf G Heine10,13 MOSAIC Study Investigator Group

ABSTRACT

Objectives The MOSAIC study aimed to evaluate if the Cow’s Milk-related Symptom Score (CoMiSS) can be used as a stand-alone diagnostic tool for cow’s milk protein allergy (CMPA).

Design Single-blinded, prospective, multicentre diagnostic accuracy study.

Setting 10 paediatric centres in China.

Participants 300 non-breasted infants (median age 16.1 weeks) with suspected CMPA.

Interventions After performing the baseline CoMiSS, infants commenced a cow’s milk protein elimination diet with amino acid-based formula for 14 days. CoMiSS was repeated at the end of the elimination trial. Infants then underwent an open oral food challenge (OFC) with cow’s milk-based formula (CMF) in hospital. Infants who did not react during the OFC also completed a 14-day home challenge with CMF. A diagnosis of CMPA was made if acute or delayed reactions were reported.

Primary outcome measures A logistic regression model for CoMiSS to predict CMPA was fitted and a receiver-operator characteristic (ROC) curve generated. An area under the curve (AUC) of ≥0.75 was deemed adequate to validate CoMiSS as a diagnostic tool (target sensitivity 80%–90% and specificity 60%–70%).

Results Of 254 infants who commenced the OFC, 250 completed both challenges, and a diagnosis of CMPA made in 217 (85.4%). The median baseline CoMiSS in this group fell from 8 (IQR 5–10) to 5 (IQR 3–7) at visit 2 (p<0.000000001), with a median change of −3 (IQR −6 to −1). A baseline CoMiSS of ≥12 had a low sensitivity (20.3%), but high specificity (87.9%) and high positive predictive value (91.7%) for CMPA. The ROC analysis with an AUC of 0.67 fell short of the predefined primary endpoint.

Conclusions The present study did not support the use of CoMiSS as a stand-alone diagnostic tool for CMPA. Nevertheless, CoMiSS remains a clinically useful awareness tool to help identify infants with cow’s milk-related symptoms.

Strengths and limitations of this study

- The Cow’s Milk-related Symptoms Score (CoMiSS), a widely used clinical awareness tool, was designed to help primary healthcare providers in identifying infants with cow’s milk-related symptoms.
- This single-blinded, prospective, multicentre study (MOSAIC study) in 300 Chinese infants with suspected cow’s milk allergy was adequately powered to assess if CoMiSS could be used as a stand-alone diagnostic tool for cow’s milk protein allergy (CMPA).
- Following the Standards for Reporting of Diagnostic Accuracy Studies 2015 guidelines for reporting diagnostic accuracy studies, the study validated CoMiSS as the index test against the reference standard for a diagnosis of CMPA, the oral food challenge (OFC).
- The primary study endpoint was based on the area under the curve of the receiver operating characteristic curve, in line with established diagnostic standards.
- While the open OFC with predefined, objective stopping criteria is generally considered adequate for a diagnosis of CMPA in infants, the lack of double-blinding of the OFC in the present study may have introduced confirmation bias into the challenge readout.
the diagnosis of non-IgE-mediated CMPA may be difficult due to the delayed onset of symptoms and overlap with other common paediatric conditions, such as infantile colic, gastro-oesophageal reflux, gastrointestinal infection or lactose intolerance. In addition, apart from an oral food challenge (OFC) with cow’s milk, there is currently no diagnostic test for non-IgE-mediated CMPA.

The Cow’s Milk-related Symptom Score (CoMiSS) was originally developed as an awareness tool, can be used as a stand-alone diagnostic tool for CMPA in infants. The CoMiSS tool generates a score based on gastrointestinal, dermatological, respiratory and general symptoms (total score range 0–33) which may be associated with CMPA (online supplemental figure S1). A pilot study suggested that a CoMiSS ≥12, in conjunction with a ≥50% score reduction following a cow’s milk protein (CMP) elimination diet was suggestive of a diagnosis of CMPA. Several studies have assessed the diagnostic accuracy of CoMiSS in predicting CMPA, as well as tracking the clinical response to an elimination diet. While the clinical usefulness of predicting CMPA by CoMiSS was suggested in some of these studies, none was adequately designed to formally validate CoMiSS as a diagnostic tool. Two recent systematic reviews have concluded that CoMiSS may be useful in monitoring the clinical response to an elimination diet but found published data insufficient to recommend CoMiSS as a diagnostic tool for CMPA.

The aim of the present study was to evaluate if CoMiSS, originally developed as an awareness tool, can be used as a stand-alone diagnostic tool for CMPA in infants. Secondary objectives included the assessment of sensitivity and specificity of the baseline CoMiSS before any dietary intervention, as well as the performance of individual clinical domains of CoMiSS. The primary endpoint of the present study was based on the area under the curve (AUC) of the receiver operating characteristic (ROC) for a logistic regression model used to predict CMPA. The ROC curve plots sensitivity against 1-specificity for different thresholds of the probability of CMPA predicted by the logistic regression model. An AUC of 1.0 demonstrates perfect discrimination between diagnostic groups, and an AUC of 0.5 indicates discrimination no better than chance. There is debate about the usefulness of diagnostic tests with AUC values below 1.0. A common view is that an AUC of 0.8–0.9 generally indicates good to excellent diagnostic accuracy, while an AUC between 0.7 and 0.8 is at the lower range of adequate performance. Based on these considerations, the primary hypothesis was that CoMiSS had a high sensitivity (target range 80%–90%) and at least moderate specificity (target range 60%–70%) for predicting a diagnosis of CMPA, corresponding with an AUC of at least 0.75 on the ROC analysis.

METHODS
The MOSAIC study was conducted as a single-blinded, prospective, multicentre diagnostic accuracy study in 10 clinical sites in China between December 2016 and July 2018. All parents or legal guardians of participating infants provided written informed consent at the time of enrolment in the study. The overall conduct of the study was managed and monitored by a contract research organization, George Clinical, Sydney, Australia. The independent statistical analysis was performed by Cytel, USA. The MOSAIC study was prospectively registered (NCT03004729) prior to the enrolment of the first patient and the study protocol published in a peer-reviewed journal before completion of the study.

Study design
The assessment of CoMiSS as a diagnostic tool was conducted according to the Standards for Reporting of Diagnostic Accuracy Studies (STARD) 2015 guidelines for the reporting of diagnostic accuracy studies. CoMiSS was defined as the index test and validated against the OFC as the reference standard, with a binary diagnostic CMPA status as ‘absent’/‘present’. Applying a group sequential design, the study population was randomised 1:1 into a ‘training set’ and a ‘test set’. A logistic regression model based on the baseline CoMiSS and change from baseline to visit 2 was fitted to the training set, with CMPA status as the binary response. This model was then used to predict a diagnosis of CMPA in the test set and to generate the final ROC curve. The primary study endpoint to validate CoMiSS as a diagnostic tool was based on an AUC ≥0.75 of the ROC curve in the test set.

Interventions and outcome measures
Non-breastfed infants under 6 months of age with any suspected cow’s milk-related symptoms were consecutively enrolled according to the published inclusion criteria. Symptoms had to be present for at least 1 week and have developed within the first 2 months of commencing an infant formula containing intact CMP. After the baseline assessment which included the baseline CoMiSS (visit 1), infants were fed an amino acid-based formula (AAF; Alfamino, Nestlé Health Science, Switzerland) for 14 days. In infants 4 months of age or older, a CMP-free complementary diet was permitted. At the end of the elimination trial, CoMiSS was repeated (visit 2). In addition, the likelihood of CMPA was rated by investigators on a visual analogue scale (VAS; range 0 = ‘no CMPA’ to 10 = ‘definite CMPA’) before and after the elimination trial.

After having completed the elimination trial, infants underwent an open OFC with a cow’s milk-based infant formula (CMF; NAN1, Nestlé, Switzerland) over 6 hours in hospital, following the published PRACTical ALLergy (PRACTALL) consensus report. A detailed description of the OFC procedure is provided in the published protocol. Infants who attempted the OFC comprised the intent-to-treat (ITT) analysis population. The OFC was assessed based on predefined objective stopping criteria. Investigators performing the OFC were single-blinded to the CoMiSS result and response to AAF. Infants who did not react during the day 1 OFC in hospital were asked to continue with a 14-day, open CMF challenge at home.
Subjects who completed both OFC phases were included in the per protocol (PP) analysis cohort. Any suspected allergic reactions (i.e., vomiting, diarrhoea, recurrence of rectal bleeding, increased crying or regurgitation, eczema flare) during the home challenge were verified by the research staff during a clinical visit. A diagnosis of CMPA was made if infants had reacted either during the OFC in hospital or at home.

**Sample size calculation**

A pooled data analysis from three published trials using CoMiSS for the evaluation of hypoallergenicity of formulas intended for CMPA suggested that infants having a low CoMiSS (median, 5) after 1 month of a CMP elimination diet had a high likelihood of suffering from CMPA (OR, 0.83; 95% CI 0.75 to 0.93; p=0.002). Based on that estimate, around 80 subjects with a positive OFC and 35 subjects with a negative OFC were required to test the study hypothesis regarding the AUC (with 90% power and at 5% level of significance). For the group sequential design, two cohorts of 115 infants each (training set and test set) with and without CMPA were required (total of 230 infants). Assuming a non-completer rate of 25%–30%, 300 infants needed to be enrolled.

**Interim analysis**

In view of uncertainties in the sample size estimation based on the expected prevalence of CMPA in the study cohort, a two-stage, adaptive, group sequential design was used. The main purpose of the interim analysis was to stop the trial early for efficacy or futility, or to increase the sample size if the interim AUC results for the ROC analysis fell in the ‘promising zone’. The interim analysis was planned after 146 subjects had completed the OFC sequence and was carried out in an unblinded fashion by an independent Statistical Centre. The interim decision was made by an independent Data Monitoring Committee (iDMC).

**Statistical analysis**

Descriptive statistics (mean, median, SD) were used to summarise baseline characteristics of the study cohort, including CoMiSS. The IQR indicates the range between the 25th and 75th percentiles. The change in CoMiSS from baseline to visit 2 was assessed by the Wilcoxon signed-rank test for paired data, and the change in VAS scores by paired t-test. Based on 2×2 contingency tables of a CoMiSS cut-off ≥12 by CMPA status, sensitivity, specificity, positive predictive values (PPVs) and negative predictive value (NPV) were calculated. This analysis was performed both for the baseline CoMiSS ≥12 alone, and for CoMiSS ≥12 in combination with a 50% percentage reduction from baseline. In addition, a sensitivity analysis assessed the diagnostic accuracy of CoMiSS for lower cut-off values (≥5 to ≥11). All statistical analyses were performed at the two-sided 5% level.

**Patient and public involvement**

There was no patient or public involvement.

**RESULTS**

Of 300 infants enrolled, one subject was excluded due to a missing baseline CoMiSS. The baseline characteristics of all infants with an evaluable CoMiSS (n=299) are shown in table 1. Forty-six (15.3%) infants were withdrawn by their parents before the OFC; the reasons for early withdrawal were not systematically documented. The remaining 254

---

**Table 1  Baseline characteristics**

<table>
<thead>
<tr>
<th>All infants</th>
<th>CMPA</th>
<th>Non-CMPA</th>
<th>Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=299</td>
<td>n=217</td>
<td>n=33</td>
<td>n=49</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>178 (59.5%)</td>
<td>126 (58.1%)</td>
<td>21 (63.6%)</td>
</tr>
<tr>
<td>Female</td>
<td>121 (40.5%)</td>
<td>91 (41.9%)</td>
<td>12 (36.4%)</td>
</tr>
<tr>
<td>Gestational age, median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at enrolment, median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>299 (100%)</td>
<td>217 (100%)</td>
<td>33 (100%)</td>
</tr>
<tr>
<td>Method of delivery, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal</td>
<td>151 (50.7%)</td>
<td>114 (52.8%)</td>
<td>17 (51.5%)</td>
</tr>
<tr>
<td>C-section</td>
<td>147 (49.3%)</td>
<td>102 (47.2%)</td>
<td>16 (48.5%)</td>
</tr>
<tr>
<td>Birth weight, median (IQR)</td>
<td>kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cm</td>
<td>50.0 (49.0–50.0)</td>
<td>50.0 (50.0–51.0)</td>
<td>50.0 (49.0–50.0)</td>
</tr>
<tr>
<td>Weight, median (IQR)</td>
<td>kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length, median (IQR)</td>
<td>cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head circumference, median (IQR)</td>
<td>cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline CoMiSS, median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CMPA, cow’s milk protein allergy; CoMiSS, Cow’s Milk-related Symptom Score.
Open access

(84.6%) infants completed the CMP elimination diet with AAF and attempted the OFC (ITT cohort). Of the 254 infants in the ITT set, 250 infants completed both stages of the OFC (PP cohort). The parents of four infants did not want to proceed with the 14-day home challenge and withdrew from the study.

**Interim analysis**

The single interim look was carried out at 53.3% information fraction (n=160 subjects), with an associated 0.35% alpha spent. The interim ROC analysis of the training set (n=80) found an AUC of 0.604 (sensitivity 69%, specificity 51%) which crossed the futility boundary. However, as recruitment at the time of the iDMC meeting had progressed fast and was nearly at the planned study end, the recommendation was to continue the trial to the final sample size of 300 infants. In addition, the statistical analysis plan was simplified towards a single final analysis of the entire ITT cohort.

**OFC outcomes**

Of 254 infants who attempted the OFC in hospital, 184 (72.4%) had a clinical reaction to CMF during the day 1 hospital challenge. Of the remaining 70 (27.6%) infants, 66 (26.0%) completed the 14-day home challenge. Of these, 33 (13.0%) were diagnosed with CMPA. Combining positive challenges from both OFC stages, a total of 217 (85.4%) infants had CMPA. A diagnosis of CMPA was excluded in 33 (13.0%) infants. A detailed description of the OFC outcomes has previously been published.27

Atopic dermatitis was by far the most common presentation in both groups (54% vs 45%). There were minor differences in the clinical characteristics between the CMPA and non-CMPA groups. While rectal bleeding and regurgitation/vomiting were more commonly seen in infants with CMPA, infants in the non-CMPA group had a greater representation of constipation, persistent crying and respiratory symptoms. However, none of these differences was statistically significant, in part due to low numbers. The clinical presentation of infants in the PP cohort is summarised in table 2.

**CoMiSS scores at baseline and change after the elimination trial**

In the population of infants with evaluable data, the median baseline CoMiSS was 8 (IQR 5–10; range 0–24). Infants with CMPA had a higher CoMiSS at baseline, compared with CMPA-negative infants; 8 (IQR 6–11) versus 5 (IQR 4–10). In the infants with confirmed CMPA, there was a highly significant reduction in CoMiSS from 8 (IQR 6–11) to 5 (IQR 3–7) from baseline to visit 2 (p<0.000000001), with a median reduction by −3 (IQR −6 to −1). A lesser reduction was observed in the infants without CMPA where CoMiSS fell from 5 (IQR 4–10) to 3.5 (IQR 2–7), with a median change of −2 (IQR −5 to −1); p=0.0013. The absolute decrease in CoMiSS values from baseline to visit 2 was significantly greater in infants with high baseline scores (adjusted r²=0.568; p<0.000001). CoMiSS scores at baseline and visit 2 are summarised in figure 1 and online supplemental table S1 (in supplemental materials).

**Individual CoMiSS domains**

In the present study, the composite CoMiSS was mainly made up of scores from the stool, eczema and respiratory symptom domains, while crying and regurgitation contributed to a much lesser extent. In the CMPA group, the reduction in scores for each clinical domain following the elimination diet was highly significant, while in the non-CMPA group changes were less pronounced or non-significant (crying, regurgitation, urticaria). Thirty-nine (15.6%) infants in the PP cohort had presented with rectal bleeding, suggestive of food protein-induced proctocolitis. As rectal bleeding is not part of the CoMiSS design, this clinical manifestation did not contribute to composite scores. Depending on concomitant symptoms, infants with rectal bleeding had total CoMiSS values ranging from 0 to 3. The skin scores

<table>
<thead>
<tr>
<th>Main clinical presentation</th>
<th>CMPA n=217</th>
<th>No CMPA n=33</th>
<th>Total n=250</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic dermatitis/eczema</td>
<td>118 (54.4%)</td>
<td>15 (45.5%)</td>
<td>133 (53.2%)</td>
</tr>
<tr>
<td>Rectal bleeding</td>
<td>35 (16.1%)</td>
<td>4 (12.1%)</td>
<td>39 (15.6%)</td>
</tr>
<tr>
<td>Persistent diarrhoea</td>
<td>23 (10.6%)</td>
<td>4 (12.1%)</td>
<td>27 (10.8%)</td>
</tr>
<tr>
<td>Regurgitation/vomiting</td>
<td>23 (10.6%)</td>
<td>1 (3.0%)</td>
<td>24 (9.6%)</td>
</tr>
<tr>
<td>Constipation</td>
<td>6 (2.8%)</td>
<td>3 (9.1%)</td>
<td>9 (3.6%)</td>
</tr>
<tr>
<td>Persistent crying/irritability</td>
<td>5 (2.3%)</td>
<td>2 (6.1%)</td>
<td>7 (2.8%)</td>
</tr>
<tr>
<td>Poor weight gain</td>
<td>5 (2.3%)</td>
<td>0 (0%)</td>
<td>5 (2.0%)</td>
</tr>
<tr>
<td>Respiratory symptoms</td>
<td>0 (0%)</td>
<td>3 (9.1%)</td>
<td>3 (1.2%)</td>
</tr>
<tr>
<td>Feeding difficulties</td>
<td>0 (0%)</td>
<td>1 (3.0%)</td>
<td>1 (0.4%)</td>
</tr>
<tr>
<td>Other/not documented</td>
<td>2 (0.9%)</td>
<td>0 (0%)</td>
<td>2 (0.8%)</td>
</tr>
</tbody>
</table>

CMPA, cow’s milk protein allergy.
were almost entirely due to atopic dermatitis, as only 11 infants had urticaria at baseline (CMPA n=9, non-CMPA n=2). Urticaria persisted to visit 2 in 4 infants (CMPA n=3, non-CMPA n=1). The change in CoMiSS for individual clinical domains is summarised in figure 1 and online supplemental table S1.

**Diagnostic accuracy assessment of CoMiSS**

The study flow diagram according to the ‘STARD’ is shown in figure 2.23 Sensitivity, specificity, PPV and NPV were calculated based on 2×2 contingency tables for the PP cohort (online supplemental table S2). Applying a cut-off of ≥12, the baseline CoMiSS had a low sensitivity of 20.3%, but was highly specific for CMPA (87.9%) and had a high PPV (91.7%). A sensitivity analysis of a range for cut-off values showed that for lower cut-off values the sensitivity generally improved, but at the expense of specificity. Combining the baseline cut-off with a ≥50% reduction in CoMiSS also improved the specificity but further reduced the sensitivity. The best diagnostic accuracy was found for a baseline CoMiSS ≥6 (sensitivity 78.8%, specificity 51.5%); online supplemental table S2.

Similar findings were observed in the single final ROC analysis of the PP cohort. The estimated logistic regression model was (logit \( \text{CMPA} = 0.378 + (0.252 \times \text{baseline CoMiSS}) + (0.065 \times \text{delta CoMiSS V1–V2}) – (0.017 \times \text{interaction of baseline and delta CoMiSS V1–V2}) \)). Based on this ROC model, the AUC was 0.67 which fell short of the primary study endpoint of AUC ≥0.75; figure 3.

**Investigator assessment of likelihood of CMPA by VAS**

Paired VAS data on investigator assessment of the likelihood of CMPA were available for 251 (99%) infants in the ITT cohort. The mean VAS slightly decreased from 7.15 (SD 1.47) at baseline to 6.76 (SD 2.1) at visit 2; paired t-test \( p=0.0164 \). In infants with CMPA (n=217), investigators were less confident of a diagnosis of CMPA with a decrease in VAS from 7.26 (SD 1.43) to 6.86 (SD 2.07); paired t-test \( p=0.0039 \). Overall, there was poor correlation between the VAS at baseline or visit 2 with corresponding CoMiSS values (baseline, \( r=0.1 \); visit 2, \( r=0.16 \)).

**Impact of birth mode on baseline CoMiSS and CMPA**

In the ITT set, 131 infants were born via caesarean section, and 118 via vaginal delivery. There was no significant association between birth mode and CMPA status (CMPA rate: caesarean section 94% (114/131) vs vaginal delivery 86% (102/118); \( \chi^2=0.018; p=0.89 \). In addition, there were no statistically significant differences between the baseline CoMiSS of infants born via caesarean section,
compared with vaginally delivered infants (median baseline CoMiSS: 7 (IQR 6–10) vs 8 (IQR 5–10.5); N.S.).

**Reporting of other secondary study objectives**

Of the 11 secondary objectives defined in the published protocol,22 7 are reported here. The anthropometric outcomes to 9 months of age of the CMPA cohort have previously been published.27 The assessment of the impact of a family history of atopy on baseline CoMiSS and the prevalence of CMPA was omitted due to missing data. We also omitted the assessment of compliance with the elimination diet and of the therapeutic effect of an AAF-based diet as supporting data were not collected.

**DISCUSSION**

The present diagnostic accuracy study conducted in 300 Chinese infants was the first to attempt a formal validation of CoMiSS as a stand-alone diagnostic tool for CMPA. More precisely, the AUC of 0.67 remained below the predefined cut-off of at least 0.75. CoMiSS fell significantly from baseline to the end of the CMP elimination diet, with a greater reduction seen in the infants with CMPA. CoMiSS may therefore have a role in monitoring the response to a diagnostic elimination diet, as previously suggested.15 The significant score reduction observed in the non-CMPA group may be due to several factors, including the treatment of atopic dermatitis with moisturisers and/or topical corticosteroids which is likely to have reduced skin findings and which may indirectly have improved crying or sleep behaviours.26 In addition, a non-specific placebo effect after formula change, parental support during a clinical trial and a time effect in conditions that tend to improve spontaneously (eg, viral gastrointestinal or respiratory infections) may also have contributed to a decrease in scores.

Applying the recommended cut-off of ≥12, with or without a 50% score reduction after the elimination trial, CoMiSS was highly specific (range 87.5%–87.9%) for CMPA but lacked sensitivity (range 14.0%–20.3%); online supplemental table S2. Lowering the cut-off values generally improved the sensitivity, but at the expense of specificity, with the best combination achieved for a CoMiSS cut-off of ≥6. This aligns with another recent Chinese study which found the best-performing diagnostic cut-off values between 5 and 6.19 By comparison, the optimum diagnostic cut-off in a recent Italian study17 was ≥9 which corresponds with the 95th percentile in a study on CoMiSS in 413 presumed healthy European infants from Belgium, Italy, Poland and Spain.29 In that study, the median CoMiSS was 3 which is similar to the value of 3.5 (IQR 2–7) found in the non-CMPA at visit 2. By contrast, infants with CMPA in the present study had higher CoMiSS values at visit 2 (median 5; IQR 3–7), suggesting differences between populations or an incomplete response after 2 weeks of AAF treatment.

The composite CoMiSS in Chinese infants in our study was mainly made up of scores for the skin, respiratory and stool domains. This included more than 50% of infants with atopic dermatitis, and about 15% had presented with rectal bleeding. Even though atopic dermatitis and rectal bleeding are well-recognised manifestations of CMPA, the high proportion of infants in the present study with these conditions differs from the clinical spectrum described in European studies.17 The design of CoMiSS emphasises the importance of persistent crying, regurgitation and abnormal stools, in line with clinical practices in Europe.13 Accordingly, two studies from Italy and India mostly included infants with a combination of these symptoms.16 17 By contrast, a study on CoMiSS from Turkey found that the presence of eczema was the most useful predictor of CMPA.18 A low number of symptoms, low scores for crying and regurgitation, as well as a significant number of infants with rectal bleeding may explain the generally lower CoMiSS values (median, 8) in the present study, compared with previous trials.17-19 These data suggest regional differences in the clinical spectrum of CMPA, as well as potential differences in perceptions by parents and primary care practitioners, for example, regarding persistent crying and regurgitation in infants. Differences in language...
and interpretation of CoMiSS may also affect its performance as a diagnostic tool.\textsuperscript{19} 29 Future adaptations of the CoMiSS tool should therefore re-evaluate lower cut-off values in an attempt to improve the ability to identify infants with CMPA.

The present study had several limitations. The ITT cohort consisted to 85% of infants with CMPA. The early withdrawal of 46 (15%) enrolled participants due to possible non-response to the elimination diet may have enriched the ITT cohort for a diagnosis of CMPA. In addition, the lack of a double-blind OFC may have led to an overestimation of CMPA. In addition, the lack of blinded, open OFC with predefined, objective stopping criteria are generally considered sufficient for a diagnosis of CMPA in infants, as even double-blind, placebo-controlled food challenges in this age group may be prone to errors.\textsuperscript{30} 31 A significant proportion of infants in our study had atopic dermatitis at the time of the OFC which could point to concomitant food allergies (eg, egg allergy) or incomplete treatment. Skin flares unrelated to CMPA may thus have confounded challenge outcomes. In addition, rectal bleeding which was not captured by CoMiSS may have reduced the diagnostic accuracy of the tool. The present study did not define the type of CMPA (ie, IgE-mediated vs non-IgE-mediated). While the clinical presentation of infants was mostly suggestive of non-IgE-mediated CMPA, there was an unexpectedly high rate of immediate and possibly IgE-mediated reactions during the day 1 OFC. By contrast, there were only a small number of infants with urticarial reactions as a clinical marker of IgE-mediated CMPA. As skin prick testing or serum IgE antibody testing was not included in the protocol, this discrepancy could not be resolved. We were therefore unable to assess if CoMiSS performs equally well in infants with IgE-mediated or non-IgE-mediated CMPA. Similarly, our study only assessed CoMiSS in formula-fed infants, and its usefulness in breastfed infants requires further study.

In summary, the present study in Chinese infants found that CoMiSS lacked accuracy as a stand-alone diagnostic test for CMPA. The spectrum of CMPA manifestations was associated with generally low CoMiSS values which overlapped with the scores found in presumably healthy European infants.\textsuperscript{20} These findings indicate that the clinical spectrum of CMPA may differ between regions, with a lower prevalence of infantile colic and functional gastrointestinal symptoms in infants in China compared with European infants.\textsuperscript{32–34} In the Chinese infants of this study, a baseline CoMiSS \( \geq 12 \) was highly predictive and specific for CMPA but lacked sensitivity. Other studies, as well as data in healthy infants, suggested that a lowering of the CoMiSS cut-off could improve its overall performance.\textsuperscript{17} 29 At this stage, a diagnosis of CMPA still requires both a clear response to CMP elimination and a clinical recurrence of symptoms during a confirmatory OFC.\textsuperscript{18} In this process, CoMiSS may be used to document the change in symptoms after a CMP elimination.\textsuperscript{12} 15 If a confirmatory OFC is not feasible or declined by parents, a baseline CoMiSS of 12 or higher, in conjunction with an unequivocal clinical response to CMP elimination, was highly specific and predictive and may thus support a diagnosis of CMPA. Of note, CoMiSS is not suitable for infants with suspected food protein-induced proctocolitis or food protein-induced enteropathy syndrome (FPIES) as these conditions are outside its scope and design.\textsuperscript{13} In conclusion, CoMiSS did not demonstrate the required accuracy of a stand-alone diagnostic test for CMPA but remains a clinically useful awareness tool in primary care for the early identification of infants with cow’s milk-related symptoms.\textsuperscript{14}

**Author affiliations**

1Vrije Universiteit Brussel, UZ Brussel, KidZ Health Castle, Brussels, Belgium
2Children’s Hospital Zhejiang, University School of Medicine, Zhejiang University, Hangzhou, China
3Cybel Inc, Waltham, Massachusetts, USA
4Department of Paediatrics, Hôpital Necker-Enfants Malades, Paris, France
5Department of Infants and Adolescents, University Hospitals Geneva, Geneva, Switzerland
6New Children’s Hospital, Helsinki University Central Hospital, Helsinki, Finland
7Paediatric Gastroenterology, La Fe University and Polytechnic Hospital, Valencia, Spain
8Department of Paediatrics, Medical University of Warsaw, Warsaw, Poland
9Research Institute, Department of Paediatrics, Marien-Hospital Wesel, Wesel, Germany
10Department of Paediatrics, Imperial College London, London, UK
11Department of Paediatrics, Hospital ‘F. Del Ponte’, University of Insbruck, Varese, Italy
12Institute for Gastroenterology, Nutrition and Liver Disease, Schneider Children’s Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
13Nestlé Health Science, Vevey, Switzerland

**Acknowledgements** The authors wish to thank all families and research staff involved with the study. The contribution of the principal investigators in China (MOCAI Study Investigator Group) and research staff at each of the 10 study sites is gratefully acknowledged.

**Collaborators** MOCAI Study Investigator Group: Zheng-Yan Zhao, Children’s Hospital Zhejiang, University School of Medicine, Hangzhou, Zhejiang, China (lead); Xiaomei Tong, University Third Hospital, Beijing, China; Yan Hu, Children’s Hospital of Chongqing Medical University, Chongqing, China; Liyan Zhang, Children’s Hospital of Fuzhou, Fujian, China; Jieliu Wu, Maternal and Child Health Care Hospital, Guangzhou, Guangdong, China; Shufen Yang, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China; Xiao Qin Li, Children’s Hospital of Zhengzhou, Henan, China; Yan Zhong, Hunan Children’s Hospital, Hunan, China; Jinjin Chen, Children’s Hospital of Shanghai, Shanghai, China; Qing Zhao, Children’s Hospital of Shaxi Women Health Center, Taiyuan, Shanxi, China.

**Contributors** YV and RGH were responsible for the concept and design of the study. Z-YZ was the lead principal investigator for China who coordinated the study execution in the 10 study sites. RA performed the independent statistical analysis. All authors have actively participated in the study readout and interpretation of findings. YV and RGH wrote the first draft of the manuscript. All authors participated in the editing process and have approved the final version of the manuscript. YV and Z-YZ have contributed equally to the manuscript and are joint first authors. YV and RGH are responsible for the overall content as the guarantor.

**Funding** This trial was sponsored by Nestlé Health Science (Grant number: not applicable).

**Competing interests** YV has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Abbott Nutrition, Biogaia, Bioceodex, Danone, Hero, Hipp, Johnson & Johnson, Mead Johnson, Merck, Menarini, Nestlé Nutrition Institute, Nutricia, Orfraf, Pfizer, Phacelob, Sari Husada, Shire (Movetsil), Sucampato, Takeda, United Pharmaceuticals, Wyeth and Yakult. CD has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Abbott Nutrition, Danone, Novacal, Nestlé Nutrition Institute, Nutricia, Solidac, United Pharmaceuticals and Wyeth. BB has received lecture honoraria from Danone and Solitdac, and has received research grants from Nestlé. CR-K has participated as consultant and/or speaker for Mead Johnson International, Hero Institute, Alter-Nutrien, Danone and Nestlé. HS has participated as a clinical investigator and/or speaker for Ausnutria, Arla, Biogaia, Bioceodex, Danone, Dicoform, Else Nutrition, HIPP, Nestlé, Nestlé Nutrition Institute, Nutricia, Mead Johnson, Myor and Merck. KB has received lecture honoraria from Nestlé.
SS has participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Danone, Dicofarm, DVA, Nestlé and United Pharmaceuticals. RS has participated as clinical investigator, and/or advisory board member, and/or consultant and/or speaker for Abbott, Else, Nestlé Nutrition Institute, NGS and Nutricia. AJ and RGH are full-time employees of Nestlé Health Science. The other authors have disclosed no conflict of interest relevant to this article.

Patient consent for publication Not applicable.

Ethics approval The present study was approved by the Medical Ethics Committee at Hunan Children's Hospital, Hunan, China (HCHLL-[8-1016]). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data are available upon request from the Chief Science & Medical Officer, Nestlé Health Science, OH-1900 Vevey, Switzerland.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Author note CoMiSS™ is a Registered Trademark of Société des Produits Nestlé SA, Switzerland.

ORCID iD Ralf G Heine http://orcid.org/0000-0002-3343-0379

REFERENCES